Previous 10 | Next 10 |
Dermira (NASDAQ: DERM ) +29% on apparent reaction to AnaptysBio's etokimab flop in a mid-stage atopic dermatitis study. More news on: Dermira, Inc., ObsEva SA, Sientra, Inc., Stocks on the move, Read more ...
Iovance Biotherapeutics (NASDAQ: IOVA ) is up 12% premarket on light volume in reaction to new data from a Phase 2 clinical trial, C-144-01 , evaluating lifileucel, an autologous adoptive cell transfer therapy, in metastatic melanoma patients. The results were presented at the...
- Cohort 2 objective response rate (ORR) as determined by independent review committee (IRC) was 35 percent, which aligns well with the investigator assessed ORR of 36 percent - - Median duration of response (DOR) was not reached as assessed by IRC or investigator at 11.3 months of study ...
SAN CARLOS, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that the company plans to present at the fo...
Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...
Image source: The Motley Fool. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Q3 2019 Earnings Call Nov 04, 2019 , 4:30 p.m. ET Operator Continue reading
Iovance Biotherapeutics, Inc. (IOVA) Q3 2019 Earnings Conference Call November 4, 2019 4:30 PM ET Company Participants Tim Morris – Chief Financial Officer Maria Fardis – President and Chief Executive Officer Friedrich Finckenstein – Chief Medical Officer ...
Iovance Biotherapeutics (NASDAQ: IOVA ): Q3 GAAP EPS of -$0.40 misses by $0.01 . Cash, cash equivalents, and short-term investments of $361.87M Press Release More news on: Iovance Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
- Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01 melanoma trial - ...
SAN CARLOS, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2019 ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
8.86%Change Percent:
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
2024-07-29 18:24:26 ET No investor likes it when one of their stocks is hit with a recommendation downgrade from an analyst. That was the dynamic behind Iovance Biotherapeutics ' (NASDAQ: IOVA) more than 2% decline in value on Monday. A onetime Iovance bull has considerably cooled o...
SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and...
2024-07-29 05:15:07 ET Piper Sandler analyst issues NEUTRAL recommendation for IOVA on July 29, 2024 02:11AM ET. The previous analyst recommendation was Overweight. IOVA was trading at $9.25 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...